Dr. Andrew McNeill joined Chromacity as a board member and executive Chairman in 2017. He also manages new investments at EOS Tech Investors. Over the last 15 years, he has specialised in building venture backed, technology and medical device businesses based on strong intellectual property.
Prior to joining Chromacity, Andrew was CEO of Fixed Phage, a Glasgow based biotechnology company. Previously he was CSO for the orthopaedic biotech company Taragenyx and dermatology company Ambicare Health.
Andrew has a PhD in Molecular Physics from the University of Leeds.